Arpeggio Bio
YC S19Boulder, US · Founded 2018 · Delaware corporation · 20 employees · 8 known investors
Find your way into Arpeggio Bio
482 people in our graph share verified history with the Arpeggio Bio team — schools, employers, funds. One of them is your warm intro.
Garry Tanunlockedknows Joey Azofeifa · together at Y Combinator (overlapped)
×10knows the team · via Y Combinator
knows the team · via University of Colorado Boulder
Arpeggio Bio develops pharmaceutical drugs that target transcription factors using artificial intelligence and RNA-sequencing technology, with lead programs in development for melanoma treatment and rare disease applications.
Also known as Arpeggio Biosciences
Founders & leadership· Y Combinator alumni (S19)
Arpeggio Bio was founded in 2018 by Joey Azofeifa.
JA
Joey AzofeifainFounder & CEO2019–2026Founder of Arpeggio Bio, which develops pharmaceutical drugs targeting transcription factors using artificial intelligence and RNA-sequencing technology for melanoma and rare disease applications.30 Under 30 2020
LN
Laura NorrisinCOO & Co-founder
TR
Timothy ReadExecutive
EM
Eric MartininChief Scientific Officer2022–2023
Board
AM
Amit MehtaBoard director
Investors · 8
Fifty YearsSan Francisco · $250K – $2M
FundersClubSan Francisco · $250K – $5M
Tau VenturesPalo Alto · $500K
venBio PartnersSan Francisco
Y CombinatorSan Francisco · $500K
BoxOne VenturesreportedMontréal · $500K
venBio Global StrategicreportedSan Francisco
Westlake Village BioPartnersreportedLos Angeles · $100K – $5Mvia David Allison · board
Reported raises · per SEC filings
Form D private placements$46.4M disclosed across 5 rounds · 2019–2025
▶$20MraisedNov 2025 · 12 investors · Other TechnologyRule 506(b)
▶$20MraisedNov 2025 · 12 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Timothy ReadExecutive Officer
- Laura NorrisExecutive Officer
- David AllisonDirector
- Joseph G. AzofeifaExecutive Officer, Director
- Mira ChaurushiyaDirector
- Samuel KintzDirector
- Aaron RoystonDirector
- Offering amount
- $35.3M
- Amount sold
- $20M
- First sale
- Nov 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4MraisedMar 2025 · 14 investors · Other TechnologyRule 506(b)
▶$4MraisedMar 2025 · 14 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Amit MehtaDirector
- Timothy ReadExecutive Officer, Director
- Laura NorrisExecutive Officer, Director
- Joseph G. AzofeifaExecutive Officer, Director
- Offering amount
- $4.6M
- Amount sold
- $4M
- First sale
- Mar 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20.2MraisedSep 2022 · 28 investors · Other TechnologyRule 506(b)
▶$20.2MraisedSep 2022 · 28 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Amit MehtaDirector
- Laura NorrisExecutive Officer, Director
- Joseph G. AzofeifaExecutive Officer, Director
- Timothy ReadExecutive Officer, Director
- Eric MartinExecutive Officer
- Offering amount
- $20.3M
- Amount sold
- $20.2M
- First sale
- Aug 2022
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$2MraisedSep 2019 · 5 investors · Other TechnologyRule 506(b)
▶$2MraisedSep 2019 · 5 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Joseph G. AzofeifaExecutive Officer, Director, Promoter
- Timothy ReadDirector, Promoter
- Joe McMahonDirector
- Daniel WeaverPromoter
- Robin D. Dowell-DeenPromoter
- Laura NorrisExecutive Officer
- Offering amount
- $3M
- Amount sold
- $2M
- First sale
- Aug 2019
- Incorporated
- Corporation, Colorado, 2017
- Federal exemptions
- 06b
▶$125KraisedAug 2019 · 1 investors · Other TechnologyRule 506(b)
▶$125KraisedAug 2019 · 1 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Laura NorrisExecutive Officer
- Robin D. Dowell-DeenPromoter
- Daniel WeaverPromoter
- Timothy ReadDirector, Promoter
- Joseph G. AzofeifaExecutive Officer, Director, Promoter
- Joe McMahonDirector
- Offering amount
- $500K
- Amount sold
- $125K
- First sale
- Aug 2019
- Incorporated
- Corporation, Colorado, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 7
by search overlap
BioAge Labs6 shared keywordsBIOAGE develops therapies targeting the molecular pathways that drive aging to increase healthspan and address age-related chronic diseases. The company uses data-driven approaches and bioinformatics to identify and develop its pipeline of aging-focused therapeutics.
Aro Biotherapeutics6 shared keywordsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.
Bioworld6 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Primrose Bio5 shared keywordsPrimrose Bio develops high-efficiency production systems for innovative and complex biologics, using advanced protein expression and enzyme engineering technologies deployed across commercially proven platforms. The company serves pharmaceutical developers and contract manufacturers in the biopharmaceutical industry.
Bridgebio5 shared keywordsBridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.
bio4 shared keywordsBIO is the world's largest advocacy association representing biotechnology companies and research institutions across the United States and 30+ other nations. The organization facilitates industry networking through events, conferences, and partnering software while providing cost-savings programs and advocacy services for member companies.
Epi Biologics4 shared keywordsEpibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.
Companies competing with Arpeggio Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Arpeggio Bio do?
- Arpeggio Bio develops pharmaceutical drugs that target transcription factors using artificial intelligence and RNA-sequencing technology, with lead programs in development for melanoma treatment and rare disease applications.
- Who founded Arpeggio Bio?
- Arpeggio Bio was founded by Joey Azofeifa in 2018.
- Who are Arpeggio Bio's investors?
- Arpeggio Bio's investors include Fifty Years, FundersClub, Tau Ventures, venBio Partners, Y Combinator, BoxOne Ventures, venBio Global Strategic, Westlake Village BioPartners.
- How much funding has Arpeggio Bio raised?
- Arpeggio Bio has disclosed $46.4M raised across 5 rounds.
- Where is Arpeggio Bio headquartered?
- Arpeggio Bio is headquartered in Boulder, US.